… COSMIC-313 (NCT03937219) trial found that decreased kidney … , assistant professor of medicine, Harvard Medical School. Compared with patients … balanced between the 2 treatment arms, with a mean … in patients receiving sunitinib (Sutent). DISCLOSURES: Wenxin Xu …

… for Population Sciences, Harvard Medical School, Venkataraman shared insights … Yes! There are two trials that I think are … Sutent is conventionally the second-line treatment in that population. This trial … are some phase 1 trials looking at the combination …

… Medical School. Can you discuss emerging second- and third-line treatment … of a large multicenter trial looking at Sutent (sunitinib) versus IDRX … second and third line of treatment. So those are the … there are some phase 1 trials looking at the combination of …

… there are now several trials have supported the use … Medicine, moderated a discussion on how to select treatment … several TKIs, including sunitinib [Sutent], cabozantinib, and lenvatinib [Lenvima … Lobins, DO: The SUNNIFORECAST trial [NCT03075423] mirrors the …

… DO, assistant professor of medicine and a hematologist/ … (Cabometyx). The randomized trial investigated both pancreatic and … disease sites. As sunitinib (Sutent) is approved for pancreatic … cabozantinib offers a new treatment approach in this cohort. …

… of Internal Medicine at Mayo Clinic, discusses the CABINET trial (NCT03375320) … months set by sunitinib (Sutent), another TKI approved in … [treatment], if you will, and was approved by the FDA for … the [Alliance for Clinical Trials in Oncology]. Dr Jennifer …

… antagonists, such as sunitinib (Sutent), were the historical standard of … clinical trials, participants were asked to re-evaluate their treatment choice … the phase 3 KEYNOTE-426 trial. Nat Med. Published … results from the CheckMate 9ER trial. J Clin Oncol. …

… impose tariffs on imported drugs. These tariffs are … that specializes in pharmaceuticals, biotechnology, and medical devices. With a … IVL) platform for the treatment of coronary artery disease … under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, …

… in the Department of Medical Oncology & … guidelines for second-line treatments, while emphasizing the … , pazopanib [Votrient], sunitinib [Sutent], bevacizumab [Avastin], etc, … pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer …

… features, biologies, and treatment responses. nccRCC histologies include … excluded from RCC clinical trials, which mainly enrolled … led investigator-initiated randomized trial, patients with untreated … TKI) monotherapy with sunitinib (Sutent). The study met its …